The average cost of bringing a novel drug to market is 1.8 billion dollars, and requires approximately 13.5 years of development, mostly due to failure in the toxicity and/or efficacy stages of drug development. Thus, if we can develop a rapid and sensitive in vivo test for drug toxicity and efficacy for a disease, we could save the pharmaceutical companies hundreds of millions of dollars a year in preclinical costs as well as years in preclinical development. This grant focuses on quicker generation of drugs for Alzheimer's disease, and could save billions of dollars in annual health care cost to treat these patients, improving the quality of life and health for patients, families, and care-givers affected by Alzheimer's.